Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.9 USD | -0.03% | +5.24% | -16.96% |
06-03 | Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating | MT |
06-03 | Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.96% | 1.45B | |
+53.39% | 59.28B | |
+41.42% | 40.94B | |
-5.45% | 40.17B | |
-5.16% | 28.69B | |
+12.64% | 26.63B | |
-20.81% | 18.89B | |
+30.40% | 12.46B | |
+0.01% | 12.42B | |
+26.19% | 12.26B |
- Stock Market
- Equities
- RCUS Stock
- News Arcus Biosciences, Inc.
- Transcript : Arcus Biosciences, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10